EDGAR·FLOW

Microbot Medical Inc. — Form 8-K

Filed November 16, 2026 · analyzed by the 8-K Agent
8-K ▼ Likely negative significance 48/100
What the filing says
Microbot Medical reported Q3 2026 revenue of $72,000 (down 70% from $241,000 in Q2), attributed to seasonal softness, hospital VAC approval cycles, and inventory write-downs that created negative gross margins. Despite revenue decline, the company expanded customer accounts from 10 to 12, grew procedure utilization 44% QoQ, maintains $62M cash, secured an exclusive Israeli distribution deal with Medtechnica Ltd., and projects positive gross margins by 2027 through manufacturing cost reductions and a second production line.
Why this rating

Revenue collapse (70% QoQ) on $95.7M market cap signals execution/timing risk, but offset by cash strength, customer retention, utilization growth, and international expansion. Moderate concern, not crisis-level.

View original filing on SEC.gov ↗ MBOT · stock on Yahoo Finance ↗

See more from November 16, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.